Bishuang Cai, PhD
- ASSISTANT PROFESSOR | Medicine, Liver Diseases
Research Topics:
Apoptosis/Cell Death, Atherosclerosis, Fibrosis, Immunology, Inflammation, Lysosomes/endosome, Macrophage, Membrane Proteins/Channels, Metabolism, Protein Kinases, Protein Trafficking & Sorting, Receptors, Retinoic Acid, Signal Transduction, Trafficking, Translational ResearchBishuang Cai, PhD, is Assistant Professor at the Icahn School of Medicine at Mount Sinai. She received her PhD from the University of Nebraska Medical Center, where she studied endocytic trafficking, in 2013. She then joined Dr. Ira Tabas’s lab at Columbia University Irving Medical Center as a postdoctoral research scientist to pursue translational research with an emphasis on macrophage biology in cardiometabolic diseases. Her current research focuses on defective inflammation resolution in non-alcoholic steatohepatitis (NASH) and NASH-related cardiometabolic diseases.
Inflammation resolution is mediated by specialized pro-resolving mediators (SPMs) such as lipoxins, resolvins, protectins, and maresins. These resolving mediators block inflammatory cell influx and promote the egress of inflammatory cells, serving to limit tissue damage and to enable tissue repair. However, inflammation resolution becomes defective in non-alcoholic steatohepatitis (NASH) and atherosclerosis. We aim to elucidate the mechanisms of dysregulated SPM biosynthesis in macrophages and its consequences to NASH/atherosclerosis and identify unique pathways that hold promise for future therapies. Another focus in the lab is on the mechanistic studies of genetic variants of NASH/ atherosclerosis. The laboratory applies technologies such as transgenic mouse models, human genetics, single-cell RNA sequencing, and a variety of cell and molecular techniques.
Lab website: Bishuang Cai Laboratory
Multi-Disciplinary Training Area
Immunology [IMM]Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Cai did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.